[-] wjs018@beehaw.org 24 points 1 year ago

The type of pill that was approved is the progestin-only "mini pill" which has a much safer clinical profile than the more common-in-the-US combination pill that has both progestin and estrogen. This type of pill is already available OTC in over 100 other countries. The US is just really behind the curve on just about anything to do with reproductive rights and care.

74
submitted 1 year ago by wjs018@beehaw.org to c/science@beehaw.org

cross-posted from: https://mander.xyz/post/1133527

Paywall-free link: http://archive.today/oPjro

[-] wjs018@beehaw.org 2 points 1 year ago

So far this season...

Enjoying:

  • Horimiya
  • Zom 100

Waiting to see how it plays out:

  • Vending machine
  • Ryza
  • One Room Hero
  • Helck

Waiting to binge after the season is over:

  • Kenshin

Old show I am currently watching:

  • Science Fell in Love
[-] wjs018@beehaw.org 1 points 1 year ago

I don't blame you for dropping Ryza. I am going to give it one more episode before dropping since I have heard good things about the source from a friend that is excited about it, but so far I have found it very dull.

[-] wjs018@beehaw.org 3 points 1 year ago

Username checks out!

12
submitted 1 year ago by wjs018@beehaw.org to c/science@mander.xyz

This piece resonated with me as I also did not really envision myself working in industry when I started grad school; figuring that I would just stay in academia in one form or another. However, when I started to look outside academia (after seeing lab mates stuck in endless post-doc loops), I was surprised at the breadth of opportunities that were available.

Even though my degree was in physics, I was doing stuff relevant to several different industries. I interviewed for roles in data science, materials science, petrochemicals, food science, and pharma. Ultimately, I ended up in pharma and the very first program I worked on was an immunotherapy to target the type of cancer that caused the death of my grandfather. It wasn't some grand design on my part, just a coincidence that echoes some of what this author experienced.

[-] wjs018@beehaw.org 6 points 1 year ago

Yeah, even comments here haven't seemed to read the article. As somebody that used to install BOINC on all my machines back in the day, the reason I stopped is that many of the projects I ran (SETI being one) aren't active any longer. Also, like the article mentioned, I just don't have a desktop anymore and I am not about to run something like this on a laptop that doesn't have things like user-serviceable or replaceable parts.

[-] wjs018@beehaw.org 6 points 1 year ago

I think that @saccharomyces@mander.xyz provided a great response for the specific case of flow in a pipe.

I just want to add that if you look beyond the restrictions of flow in a pipe, there are many other types of behavior that non-Newtonian fluids exhibit. We measure this in the lab on instruments called rheometers. Basically, we put some liquid in the instrument and then deform it and measure the resistance to that deformation. One of the most common ways to apply that deformation is to do so back and forth in an oscillating manner. Depending on the frequency at which you apply this strain, the solid/liquid-like behavior can change. If you have some background in physics or want to get a decent understanding, I found this paper that, on skimming it, seems to be pretty consistent with the way I was taught this stuff in grad school.

One graph I want to point out is Figure 13 which shows what would be a "typical" viscoelastic polymer solution. An easy way to understand this graph is that as we go from left to right, we are applying strain back and forth quicker and quicker, essentially shaking it faster. When the G' value is higher than the G" value, then the material is behaving more like a solid and conversely, when G" > G', then it is behaving more like a liquid. You can see that the material goes through different phases of behavior as the strain frequency changes. Just for you I went and dug up an old graph from my thesis to show a real-life example of this happening too.

My favorite demonstration of this is to put Oobleck (or something similar) onto a speaker and then change the frequency and see what happens.

[-] wjs018@beehaw.org 0 points 1 year ago

Posted this below, but the fine is from an unrelated, earlier incident in Alabama. From what I found on jalopnik:

Earlier this year, a worker was killed by being sucked into an airplane engine in Alabama on New Year’s Eve. The employee in that scenario was warned several times that the plane’s engines would be on, however. Still, OSHA hit the small airline Piedmont with a fine of $15,625 in the workers death.

This incident with Delta that happened in Texas is under investigation. I would be surprised if no safety procedures were violated in this incident. Well-written safety procedures that are followed should make this almost impossible to happen.

[-] wjs018@beehaw.org 4 points 1 year ago

The fine is from an unrelated, earlier incident in Alabama. From what I found on jalopnik:

Earlier this year, a worker was killed by being sucked into an airplane engine in Alabama on New Year’s Eve. The employee in that scenario was warned several times that the plane’s engines would be on, however. Still, OSHA hit the small airline Piedmont with a fine of $15,625 in the workers death.

This incident with Delta that happened in Texas is under investigation.

[-] wjs018@beehaw.org 2 points 1 year ago

That's fair. I couldn't find much info on their website, so I assumed this was another make insulin cheap using "biohacking" deal. I don't have any experience with small molecule synthesis or dry powder manufacturing, so I can't really speak to how feasible this may be. However, having seen first-hand all the ways simple manufacturing steps can go wrong, the risk of consuming a medication that hasn't been through rigorous QA/QC makes me very wary.

[-] wjs018@beehaw.org 21 points 1 year ago

Apologies for the long post. I don't mean this as an attack on OP, just trying to illustrate why actually doing this is a bad idea.

I have seen efforts like this in the past, especially centered around efforts to manufacture insulin cheaply. While I get that medicine cost and availability is broken at a fundamental level in the US, the solution is a political one rather than to run a wildcat bioreactor. There is simply no way to safely manufacture biologics using a 3d printed bioreactor. Let's look at the manufacturing process to get an idea of why.

Staring with the bioreactor, you would need some way to sterilize it before use (not just sanitize, there's a difference). There are plastic bioreactors that are used in industry, but they are large, single-use bags that are sterilized using gamma or x-ray radiation. Most industry bioreactors are made of stainless steel to withstand the harsh treatment required to re-sterilize them (steam or hydrogen peroxide).

Moving down the chain from the bioreactor, you need some way to remove your product from the harvested liquid. This is usually done through lysing the cells you have grown and then running this lysate through a series of chromatography columns of varying types (affinity, ionic, etc.) to systematically remove all the junk left over from your cellular media and the cells you have lysed. Even if you could (unsafely) grow your cells and drug in a 3d printed bioreactor, you don't have these kinds of things at home and can't just get them from Amazon.

However, let's say that you could get past the purification step, what's next? You find yourself with a large volume of very dilute medicine suspended in a chromatography buffer. The next step is what is called UF/DF, or ultra-filtration/dia-filtration. This step, paradoxically done DF first, uses filter membranes and large amounts of buffer and some pressure to first swap out the buffer that your medicine is in to the target formulation that you want to inject and then concentrate it down to a manageable volume. If you are working at small scale, then you can probably replace this step with just one filter and a centrifuge. Remember that while you are doing all this, everything that comes into contact with your drug needs to be sterile (even the air).

I think I have made my point, but for actual drugs there are more steps beyond this. Post-UF/DF is what is referred to as drug substance (DS) in the industry. You still need to go through a sterile fill-finish process to get drug product (DP) that is what is actually given to a patient. If you really want, I can go on another long tirade here since this is the step my job focuses on.

I have worked on these manufacturing processes and seen them fail a lot for very hard to catch problems. Without all the in-process controls and testing we do, there would have been serious risks of giving bad DP to patients. If you have read this far, then I hope I've convinced you not to give this kind of thing a try.

The real problem this is trying to solve is a political one. We should be advocating for better access to medications and reforming how costs are dealt with. It doesn't matter what your political persuasion is, I think everyone agrees healthcare in the US is broken and it's time something is done about it.

1
submitted 1 year ago by wjs018@beehaw.org to c/academia@mander.xyz

cross-posted from: https://beehaw.org/post/698765

This article summarizes some of the challenges as well as opportunities that Ukraine is faced with in a post-Russian invasion world.

In addition to the brain-drain effect of talented scientists leaving the country, Ukraine has some structural issues as well:

The current research system is composed largely of the Soviet-style national science academy — for which the research agenda was historically set by state officials — and a university sector in which research is funded by the science ministry.

Entirely lacking is a modern, performance-based grant-giving system...the centrepiece of a new system would include funding streams for basic research, competitive grants and defence-related projects. Ukraine’s research strengths include agricultural technology, energy and planetary science

doi: https://doi.org/10.1038/d41586-023-02031-8

1
submitted 1 year ago by wjs018@beehaw.org to c/space@mander.xyz

cross-posted from: https://beehaw.org/post/697648

Exposure to microgravity causes changes to the human immune system:

"Here we show that the expression of many genes related to immune functions rapidly decreases when astronauts reach space, while the opposite happens when they return to Earth after six months aboard the ISS," said Dr. Odette Laneuville, an associate professor at the Department of Biology of the University of Ottawa, leading author of a new study in Frontiers in Immunology.

doi: https://dx.doi.org/10.3389/fimmu.2023.1171103

1
submitted 1 year ago by wjs018@beehaw.org to c/space@mander.xyz

cross-posted from: https://beehaw.org/post/659341

This article summarizes findings showing that the Spitzer telescope has observed the spectral signature of tryptophan in an extrasolar system.

This isn't the first instance of amino acids found extra-terrestrially (previously found on asteroids), but is the first found outside our solar system. Tryptophan has a very strong and very clear spectral signature (it is ubiquitously used in life sciences for example).

doi: https://dx.doi.org/10.1093/mnras/stad1535

wjs018

joined 1 year ago